#### Bone canonical Wnt signaling is downregulated in type 2 diabetes and 1 associates with higher Advanced Glycation End-products (AGEs) content and 2 reduced bone strength 3 4 Giulia Leanza MSc, PhD<sup>1,2</sup>, Francesca Cannata MSc, PhD<sup>1</sup>, Malak Faraj MSc<sup>1</sup>, Claudio Pedone 5 MD, PhD<sup>3</sup>, Viola Viola MSc<sup>1</sup>, Flavia Tramontana MSc, PhD<sup>1,2</sup>, Niccolò Pellegrini MSc<sup>1</sup>, 6 Gianluca Vadalà, MD, PhD<sup>4</sup>, Alessandra Piccoli PhD<sup>1</sup>, Rocky Strollo MD, PhD<sup>5</sup>, Francesca 7 Zalfa, MSc, PhD<sup>6,7</sup>, Alec Beeve PhD<sup>8</sup>, Erica L Scheller DDS, PhD<sup>8</sup>, Simon Tang PhD<sup>9</sup>, Roberto 8 Civitelli MD<sup>8</sup>, Mauro Maccarrone PhD<sup>10,11</sup>, Rocco Papalia MD, PhD<sup>4,\*†</sup> and Nicola Napoli MD, 9 PhD 1,2,8\*+ 10 11 <sup>1</sup> Department of Medicine and Surgery, Research Unit of Endocrinology and Diabetes, 12 Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128 Roma, Italy; 13 <sup>2</sup> Operative Research Unit of Osteometabolic and Thyroid Diseases, Fondazione Policlinico 14 Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200 – 00128, Roma, Italy; 15 <sup>3</sup> Operative Research Unit of Geriatrics, Fondazione Policlinico Universitario Campus Bio-16 Medico, Via Alvaro del Portillo, 200 – 00128, Roma, Italy; 17 <sup>4</sup> Operative Research Unit of Orthopedic and Trauma Surgery, Fondazione Policlinico 18 Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200 – 00128, Roma, Italy; 19 <sup>5</sup> Department of Human Sciences and Promotion of the Quality of Life San Raffaele Roma Open 20 University Via di Val Cannuta 247, 00166 Roma, Italy 21 <sup>6</sup> Predictive Molecular Diagnostic Unit, Pathology Department, Fondazione Policlinico 22 23 Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200 – 00128, Roma, Italy; 24 <sup>7</sup> Microscopic and Ultrastructural Anatomy Unit, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128 Roma, Italy 25 <sup>8</sup> Department of Medicine, Division of Bone and Mineral Diseases. Musculoskeletal Research 26 27 Center, Washington University School of Medicine, St. Louis, MO USA; 28 <sup>9</sup> Department of Orthopaedic Surgery, Washington University in St. Louis, St. Louis, MO, USA;

<sup>10</sup> Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via

Vetoio snc, 67100 L'Aquila, Italy;

29

<sup>11</sup> European Center for Brain Research, Santa Lucia Foundation IRCCS, 00164 Roma, Italy 31 32 33 † These authors are equally senior authors. 34 35 \*Corresponding Authors: 36 Nicola Napoli, MD PhD 37 38 Department of Medicine and Surgery Research Unit of Endocrinology and Diabetes 39 Università Campus Bio-Medico di Roma 40 Via Alvaro del Portillo 21 41 42 00128 Roma, Italy n.napoli@unicampus.it 43 44 Rocco Papalia, MD PhD 45 46 Operative Research Unit of Orthopedic and Trauma Surgery Fondazione Policlinico Campus Bio-Medico di Roma 47 48 Via Alvaro del Portillo 200 00128 Roma, Italy 49 50 r.papalia@fondazionepoliclinico.it 51 **Short title:** Wnt signaling in bone of type 2 diabetes 52 53 54 **Keywords:** Diabetes, Bone, Wnt signaling, AGEs 55 **Disclosures** 56 57 All authors have nothing to disclose relevant to this work. 58

#### Abstract

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79


80

81

82

Type 2 diabetes (T2D) is associated with higher fracture risk, despite normal or high bone mineral density. We reported that bone formation genes (SOST and RUNX2) and Advanced Glycation Endproducts (AGEs) were impaired in T2D. We investigated Wnt signaling regulation and its association with AGEs accumulation and bone strength in T2D from bone tissue of 15 T2D and 21 non-diabetic postmenopausal women undergoing hip arthroplasty. Bone histomorphometry revealed a trend of low mineralized volume in T2D [(T2D 0.249% (0.156-0.366) vs non-diabetic subjects 0.352% (0.269-0.454); p=0.053)], as well as reduced bone strength [T2D 21.60 MPa (13.46-30.10) vs non-diabetic subjects 76.24 MPa (26.81-132.9); p=0.002]. We also showed that gene expression of Wnt agonists LEF-1 (p=0.0136) and WNT10B (p=0.0302) were lower in T2D. Conversely, gene expression of WNT5A (p=0.0232), SOST (p<0.0001) and GSK3B (p=0.0456) were higher, while collagen (COLIAI) was lower in T2D (p=0.0482). AGEs content was associated with SOST and WNT5A (r=0.9231, p<0.0001; r=0.6751, p=0.0322), but inversely correlated with *LEF-1* and *COL1A1* (r= -0,7500, p=0.0255; r= -0,9762, p=0.0004). *SOST* was associated with glycemic control and disease duration (r=0.4846, p=0.0043; r=0.7107, p=0.00174), whereas WNT5A and GSK3B were only correlated with glycemic control (r=0.5589, p=0.0037; r=0.4901, p=0.0051). Finally, Young's Modulus was negatively correlated with SOST (r=-0.5675, p=0.0011), AXIN2 (r=-0.5523, p=0.0042) and SFRP5 (r=-0.4442, p=0.0437), whilepositively correlated with *LEF-1* (r=0.4116, p=0.0295) and *WNT10B* (r=0.6697, p=0.0001). These findings suggest that Wnt signaling, and AGEs could be the main determinants of bone fragility in T2D.

## Graphical abstract



#### Introduction

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

Type 2 diabetes (T2D) is a metabolic disease, with an increasing worldwide prevalence, characterized by chronic hyperglycemia and adverse effects on multiple organ systems, including bones [1]. Patients with T2D have an increased fracture risk, particularly at the hip, compared to individuals without diabetes. A recent meta-analysis reported that individuals with T2D have 1.27 relative risk (RR) of hip fracture compared to non-diabetic controls [2]. Fragility fractures in patients with T2D occur at normal or even higher bone mineral density compared to healthy subjects, implying compromised bone quality in diabetes. T2D is associated with a reduced bone turnover [3], as shown by lower serum levels of biochemical markers of bone formation, such as procollagen type 1 amino-terminal propeptide (P1NP) and osteocalcin, and bone resorption, Cterminal cross-linked telopeptide (CTX) in diabetic patients compared to nondiabetic individuals [4–7]. Accordingly, dynamic bone histomorphometry of T2D postmenopausal women showed a lower bone formation rate, mineralizing surface, osteoid surface, and osteoblast surface[8]. Our group recently demonstrated that T2D is also associated with increased SOST and decreased RUNX2 genes expression, compared to non-diabetic subjects[9]. Moreover, we have proved in a diabetic model that a sclerostin-resistant Lrp5 mutation, associated with high bone mass, fully protected bone mass and strength even after prolonged hyperglycemia [10]. Sclerostin is a potent inhibitor of the canonical Wnt signaling pathway, a key pathway that regulates bone homeostasis [11]. Diabetes and chronic hyperglycemia are also characterized by increased advanced glycation endproducts (AGEs) production and deposition [12]. AGEs may interfere with osteoblast differentiation, attachment to the bone matrix, function, and survival [13,14]. AGEs also alter bone collagen structure and reduce the intrinsic toughness of bone, thereby affecting bone

material properties [9,15,16]. In this work, we hypothesized that T2D and AGEs accumulation downregulate Wnt canonical signaling and negatively affect bone strength.. Results confirmed that T2D downregulates Wnt beta/catenin signaling and reduces collagen mRNA levels and bone strength, in association with AGEs accumulation.

#### **Materials and Methods**

## Study subjects

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

We enrolled a total of 36 postmenopausal women (15 with T2D and 21 non-diabetic controls) undergoing hip arthroplasty for osteoarthritis, consecutively screened to participate in this study between 2020 and 2022. Diabetes status was confirmed by the treating diabetes physician. Participants were diagnosed with diabetes when they had fasting plasma glucose (FPG) ≥126 mg/dl or 2-h plasma glucose (2-h PG) ≥200 mg/dl during a 75-g oral glucose tolerance test (OGTT); or hemoglobin A1c (HbA1c) ≥6.5% in accordance with the American Diabetes Association diagnostic criteria. Eligible participants were >60 years of age. Exclusion criteria were any diseases affecting bone or malignancy. Additionally, individuals treated with medications affecting bone metabolism such as estrogen, raloxifene, tamoxifen, bisphosphonates, teriparatide, denosumab, thiazolidinediones, glucocorticoids, anabolic steroids, and phenytoin, and those with hypercalcemia or hypocalcemia, hepatic or renal disorder. hypercortisolism, current alcohol or tobacco use were excluded. The study was approved by the Ethics Committee of the Campus Bio-Medico University of Rome and all participants provided written informed consent. All procedures were conducted in accordance with the Declaration of Helsinki.

Specimen preparation

Femoral head specimens were obtained during hip arthroplasty. As described previously [9], trabecular bone specimens were collected fresh and washed multiple times in sterile PBS until the supernatant was clear of blood. Bone samples were stored at  $-80\,^{\circ}\text{C}$  until analysis.

#### **Bone histomorphometry**

Trabecular bone from femur heads werefixed in 10% neutral buffered formalin for 24 h prior to storage in 70% ethanol. Tissues were embedded in methylmethacrylate and sectioned sagittally by the Washington University Musculoskeletal Histology and Morphometry Core. Sections were stained with Goldner's trichrome. Then, a rectangular region of interest containing trabecular bone was chosen below the cartilage-lined joint surface and primary spongiosa. This region had an average dimension of 45 mm². Tissue processing artifacts, such as folding and edges, were excluded from the ROI. A threshold was chosen using the Bioquant Osteo software to automatically select trabeculae and measure bone volume. Finally, Osteoid was highlighted in the software and quantified semi-automatically using a threshold and correcting with the brush tool. Unstained and TRAP-stained (Sigma) slides were imaged at ×20 high resolution using a NanoZoomer 2.0 with bright field and FITC/TRITC (Hamamatsu Photonics). Images were then analyzed via Bioquant Osteo software according to the manufacturer's instructions and published standards (v18.2.6, Bioquant Image Analysis Corp., Nashville, TN).

## **Bone compression tests**

We used cylindrical bone specimens of trabecular core (with a diameter of 10 mm and a length of 20 mm) from 10 T2D and 21 non-diabetic subjects to measure bone mechanical parameters (Young's modulus, ultimate strength and yield strength), as previously described [9].

## RNA extraction and gene expression by RT-PCR

Total RNA from trabecular bone samples was extracted using TRIzol (Invitrogen) following the manufacturer's instructions. The concentration and purity of the extracted RNA were assessed spectrophotometrically (TECAN, InfiniteM200PRO), and only samples with 260/280 absorbance ratio between 1.8 and 2 were used for reverse transcription using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA) according to the manufacturer's recommendations. Transcription products were amplified using TaqMan real-time PCR (Applied Biosystems, Carlsbad, CA) and a standard protocol (95°C for 10 minutes; 40 cycles of 95°C for 15 seconds and 60°C for 1 minute; followed by 95°C for 15 seconds, 60°C for 15 seconds, and 95°C for 15 seconds). β-Actin expression was used as an internal control (housekeeping gene). Relative expression levels of Sclerostin (*SOST*), Dickkopf-1 (*DKK-1*), Wnt ligands (*WNT5A* and *WNT10B*), T-cell factor/ lymphoid enhancer factor 1 (*LEF-1*), collagen type I alpha 1 chain (*COL1A1*), glycogen synthase kinase 3 beta (*GSK3B*), axis inhibition protein 2 (*AXIN2*), betacatenin (*BETA-CATENIN*) and secreted frizzled-related protein 5 (*SFRP5*) were calculated using the 2-<sup>ACt</sup> method.

#### **Statistical analysis**

Data were analyzed using GraphPad Prism 9.0 (GraphPad Software, San Diego, CA). Patients' characteristics were described using means and standard deviations or medians and 25th-75th percentiles, as appropriate, and percentages. Group data are presented in boxplots with median and interquartile range; whiskers represent maximum and minimum values. We assessed data for normality and Mann-Whitney test was used to compare variables between groups. Data were analyzed using nonparametric Spearman correlation analysis and the correlation coefficients (r)

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

were used to assess the relationship between variables. We used Grubbs' Test to assess and exclude outliers. **RESULTS Subject characteristics** Clinical characteristics of study subjects are presented in Table 1. T2D and non-diabetic subjects did not differ in age, BMI and menopausal age. As expected, fasting glucose was significantly higher in T2D compared to non-diabetic subjects [112.00 mg/dl (104.0-130.0) mg/dl, vs. 94.00 (87.2-106.3), respectively; p=0.009]. Median HbA1c was determined in all T2D subjects within three months before surgery [(6.95% (6.37-7.37)]. Median disease duration in T2D subjects was [14.50 years (7.25-19.25)]. Diabetes medications included monotherapy with metformin (n=12) and combination therapy with metformin plus insulin and glinide (n=3). There were no differences in serum calcium, eGFR (CKD-EPI equation) and serum blood urea nitrogen. **Bone Histomorphometry** Bone samples of 8 T2D and 9 non-diabetic subjects were used for histomorphometry analysis. We found no significant differences in BV/TV and osteoid volume, while mineralized volume/total volume (Md.V/TV) trended lower in T2D subjects relative to controls [0.249%] (0.156-0.336) vs 0.352% (0.269-0.454); p=0.053] (Table 2). **Bone compression tests** Young's modulus was lower in T2D compared to non-diabetic subjects [21.6 MPa (13.46-30.10) vs. 76.24 MPa (26.81-132.9); p=0.0025), while ultimate strength and yield strength were not different between the two groups (Table 3).

# Gene Expression

205

215

225

226

- 206 SOST mRNA was significantly higher in T2D than in non-diabetic subjects (Fig. 1A, p<0.0001),
- 207 whereas there was no difference in *DKK1* gene expression between the two groups (Fig. 1B). Of
- 208 note, SOST mRNA transcript was very low in the majority of non-diabetic subjects (Fig. 1A).
- 209 *LEF-1* (Fig. 1C, p=0.0136), *WNT10B* (*Fig. 1D*, p=0.0302) and *COL1A1* (Fig.1F, p=0.0482)
- 210 mRNA transcripts were significantly lower in T2D compared to non-diabetic subjects.
- 211 Conversely, WNT5A was higher in T2D relative to non-diabetics (Fig. 1E, p=0.0232). Moreover,
- 212 GSK3B was significantly increased in T2D compared to non-diabetic subjects (Fig.1G,
- p=0.0456), but we did not find any significant difference in gene expression of AXIN2, BETA-
- 214 *CATENIN* and *SFRP5* (Fig. 1H-J) between our groups.

### Correlation analysis of Wnt target genes, AGEs and glycemic control

- 216 As shown in figure 2, AGEs were inversely correlated with LEF-1 (Fig. 2A, p=0.0255) and
- 217 COLIAI mRNA abundance (Fig. 2B, p=0.0004), whereas they were positively correlated with
- 218 SOST (Fig. 2C, p<0.0001) and WNT5A mRNA (Fig. 2D, p=0.0322). There was no correlation
- between AGEs content and WNT10B (Fig. 2E; p=0.1938) or DKK1 gene expression (Fig. 2F;
- p=0.9349). Likewise, we did not find any significant correlation between LEF-1, WNT5A,
- 221 WNT10B, DKK-1, COL1A1 expression in bone and glycemic control in T2D individuals
- 222 (Supplemental Figure 1A-D). However, there were positive correlations between SOST and fasting
- glucose levels (Fig. 3A, p=0.0043), SOST and disease duration (Fig. 3B, p=0.00174), WNT5A,
- 224 GSK3B and fasting glucose levels (Fig. 3C, p=0.0037; Fig. 3D, p=0.0051).

Correlation analysis of Wnt target genes and bone mechanical parameters

As shown in Figure 4, Young's Modulus was negatively correlated with SOST (Fig.4A, p=0.0011), 228 AXIN2 (Fig. 4D, p=0.0042) and SFRP5 (Fig 4F, p=0.0437), while positively correlated with LEF 230 -1 (Fig. 4B, p=0.0295) and WNT10B (Fig. 4C, p=0.0001). Ultimate strength was associated with WNT10B (Fig. 4F, p=0.0054) and negatively correlated with AXIN2 (Fig. 4G, p=0.0472). Finally, 232 yield strength was associated with *LEF-1* (Fig. 4H, p=0.0495) and *WNT10B* (Fig. 4I, p=0.0020) and negatively correlated with GSK3B (Fig. 4J, p=0.0245), AXIN2 (Fig. 4K, p=0.0319), and 233 SFRP5 (Fig. 4L, p=0.0422). Non-significant correlations are reported in Supplementary figure 2 234 (A-Q). 235

#### **Discussion**

227

229

231

236

237

238

239

240

241

242

243

244

245

246

247

248

249

We show that key components of the Wnt/beta-catenin signaling are abnormally expressed in the bone of postmenopausal women with T2D and they are associated with AGEs and reduced bone strength. LEF-1, a transcription factor that mediates responses to Wnt signal and Wnt target genes itself, and WNT10B, an endogenous regulator of Wnt/β-catenin signaling and skeletal progenitor cell fate, are both downregulated in bone of postmenopausal women with T2D. Consistently, in this group, the expression of the Wnt inhibitor, SOST is increased, suggesting suppression of Wnt/β-catenin signaling. Interestingly, our data suggest that sclerostin expression is very low in healthy postmenopausal women not affected by osteoporosis. Moreover, we reported an increase in the expression level of bone GSK3B, in line with downregulated Wnt/βcatenin signaling in T2D. Our data also show that the expression of WNT5A, a non-canonical ligand linked to inhibition of Wnt/beta-catenin signaling was increased, whereas COL1A1 was decreased. These findings are consistent with reduced bone formation and suppression of Wnt signaling in T2D. We have previously reported upregulation of SOST and downregulation of

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

RUNX2 mRNA in another cohort of postmenopausal women with T2D [9]. Of note, the cohort of T2D subjects studied here had glycated hemoglobin within therapeutic targets, implying that the changes in gene transcription we identified persist in T2D bone despite good glycemic control. High circulating sclerostin has been reported in diabetes [17,18], and increased sclerostin is associated with fragility fractures [19]. Aside from confirming higher SOST expression, we also show that other Wnt/β-catenin osteogenic ligands are abnormally regulated in the bone of T2D postmenopausal women. WNT10B is a positive regulator of bone mass; transgenic overexpression in mice results in increased bone mass and strength [20], whereas genetic ablation of WNT10B is characterized by reduced bone mass [21,22], and decreased number and function of osteoblasts [21]. More to the point, WNT10B expression is reduced in the bone of diabetic mice [23]. Therefore, the reduced WNT10B in human bone we found in the present study further supports the hypothesis of reduced bone formation in T2D. Accordingly, LEF-1 gene expression was also downregulated confirming that Wnt/beta-catenin pathway is decreased in T2D. Importantly, the overexpression of LEF-1 induces the expression of osteoblast differentiation genes (osteocalcin and COL1A1) in differentiating osteoblasts [24]. In fact, in this study we also demonstrated that a downregulation of LEF-1 in T2D bone goes along with a downregulation of COL1A1, strengthen data of a reduced production of bone matrix most likely as the result of reduced osteoblasts synthetic activity in diabetes [8,25]. Reduced RUNX2 in T2D postmenopausal women also confirms previous findings [9] and further supports the notion of reduced osteoblast differentiation or function in diabetes. On the other hand, the contribution of upregulated WNT5A in diabetic bone is more complex. WNT5A regulates Wnt/beta-catenin signaling depending on the receptor availability [26]. Non-canonical WNT5A activates β-cateninindependent signaling, including the Wnt/Ca<sup>++</sup> [27] and planar cell polarity pathways [28].

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

Heterozygous Wnt5a null mice have low bone mass with impaired osteoblast and osteoclast differentiation [29]. Wnt5a inhibits Wnt3a protein by downregulating beta/catenin-induced reporter gene expression [26]. In line with these findings, we showed that there was an increased gene expression of WNT5A in bone of T2D postmenopausal women, confirming a downregulated Wnt/beta-catenin signaling and impaired osteoblasts function. Moreover, GSK3B is a widely expressed serine/threonine kinase involved in multiple pathways regulating immune cell activation and glucose metabolism. Preclinical studies reported that GSK3B is a negative regulator of Wnt/beta-catenin signaling and bone metabolism [30,31], and its increase is associated with T2D and alterations in insulin secretion and sensitivity [32,33]. Our data, confirmed that GSK3B is increased in T2D postmenopausal women and it is associated with reduced yield strength. In fact, we also showed an impaired bone mechanical plasticity in T2D, in line with other studies showing a reduced bone strength [16,34,35]. In addition, this study reported significant correlations of bone mechanical parameters and Wnt target genes, which might reflect the biological effect of downregulated Wnt signaling and AGEs accumulation on bone mechanical properties in diabetes. We have previously shown that AGEs content is higher in T2D bone compared to non-diabetic bone, even in patients with well-controlled T2D [9]. Here we show that AGEs accumulation is positively correlated with SOST, WNT5A and GSK3B gene expression, and negatively correlated with LEF-1, WNT10B, and COL1A1 mRNA. These findings are consistent with the hypothesis that AGEs accumulation is associated with impaired Wnt signaling and low bone turnover in T2D. We did not find any abnormalities in histomorphometric parameters in our subjects with T2D, consistent with our previous report [9]. Reduced osteoid thickness and osteoblast number were reported in premenopausal T2D women with poor glycemic control compared to non-

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

diabetic subjects but not in the group with good glycemic control [36]. Therefore, good glycemic control appears to prevent or rescue any changes in static histologic parameters of bone turnover that might be caused by uncontrolled diabetes. Our study has some limitations. One is the cross-sectional design; another one is the relatively small number of T2D subjects enrolled. Moreover, we measured the mRNA abundance of the genes of interest, and we cannot assume that the differences we found reflect differences in protein abundance. Although osteoarthritis may affect some of the genes we studied [37], all study subjects were affected by variable degree of osteoarthritis, and the effect of such potential confounder is not likely to be different between T2D and control subjects. Finally, we did not use the tetracycline double-labeled technique to investigate dynamic bone parameters. The main strength of our study is that this study is the first to explore the association of AGEs on Wnt pathway in postmenopausal T2D women. Moreover, we measured the expression of several Wnt genes directly on bone samples of postmenopausal T2D women. In conclusion, our data show that, despite good glycemic control, T2D decreases expression of COL1A1 and Wnt genes that regulate bone turnover, in association with increased AGEs content and reduced bone strength. These results may help understand the mechanisms underlying bone fragility in T2D.

Acknowledgements This work was supported by an internal Grant of Campus Bio-Medico University of Rome. Author Contributions: Conceptualization, N.N, R.P., M.M and R.S.; methodology, G.L., F.C., M.F., V.V., F.T., N.P., A.B., S.T..; software, G.L., C.P., A.B., and E.S.; validation, N.N. and G.L.; formal analysis, N.N. and G.L.; investigation, N.N., R.S., M.M. and R.P.; resources, N.N. G.V., R.P. M.M., and R.S.; data curation, G.L. and N.P..; writing—original draft preparation, G.L., M.F., N.P., R.C. and N.N.; writing—review and editing, G.L., N.N., C.P., N.P., F.Z., E.S., R.S. and R.C.; visualization, N.N. and R.S..; supervision, N.N., R.P., and M.M.; project administration, N.N. and G.L.; funding acquisition, N.N. and R.S. All authors have read and agreed to the published version of the manuscript. 

#### References

337

[1] Hofbauer LC, Busse B, Eastell R, Ferrari S, Frost M, Müller R, et al. Bone fragility in 338 339 diabetes: novel concepts and clinical implications. Lancet Diabetes Endocrinol 2022;10:207–20. https://doi.org/10.1016/S2213-8587(21)00347-8. 340 341 [2] Wang H, Ba Y, Xing O, Du J-L. Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis. BMJ Open 2019;9:e024067. https://doi.org/10.1136/bmjopen-2018-342 024067. 343 344 [3] Rubin MR, Patsch JM. Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directions. Bone Res 2016;4:16001. 345 https://doi.org/10.1038/boneres.2016.1. 346 Napoli N, Strollo R, Defeudis G, Leto G, Moretti C, Zampetti S, et al. Serum Sclerostin 347 [4] and Bone Turnover in Latent Autoimmune Diabetes in Adults. J Clin Endocrinol Metab 348 2018;103:1921–8. https://doi.org/10.1210/jc.2017-02274. 349 Hygum K, Starup-Linde J, Harsløf T, Vestergaard P, Langdahl BL. MECHANISMS IN 350 [5] ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover - a systematic 351 352 review and meta-analysis. Eur J Endocrinol 2017;176:R137–57. https://doi.org/10.1530/EJE-16-0652. 353 354 [6] Starup-Linde J, Vestergaard P. Biochemical bone turnover markers in diabetes mellitus -A systematic review. Bone 2016;82:69–78. https://doi.org/10.1016/j.bone.2015.02.019. 355 356 [7] Starup-Linde J, Lykkeboe S, Gregersen S, Hauge E-M, Langdahl BL, Handberg A, et al. Differences in biochemical bone markers by diabetes type and the impact of glucose. 357

Bone 2016;83:149–55. https://doi.org/10.1016/j.bone.2015.11.004. 358 [8] Manavalan JS, Cremers S, Dempster DW, Zhou H, Dworakowski E, Kode A, et al. 359 360 Circulating osteogenic precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012;97:3240–50. https://doi.org/10.1210/jc.2012-1546. 361 Piccoli A, Cannata F, Strollo R, Pedone C, Leanza G, Russo F, et al. Sclerostin [9] 362 Regulation, Microarchitecture, and Advanced Glycation End-Products in the Bone of 363 Elderly Women With Type 2 Diabetes. J Bone Miner Res 2020;35:2415–22. 364 365 https://doi.org/10.1002/jbmr.4153. Leanza G, Fontana F, Lee S-Y, Remedi MS, Schott C, Ferron M, et al. Gain-of-Function 366 367 Lrp5 Mutation Improves Bone Mass and Strength and Delays Hyperglycemia in a Mouse Model of Insulin-Deficient Diabetes. J Bone Miner Res 2021;36:1403–15. 368 369 https://doi.org/10.1002/jbmr.4303. 370 [11] Maeda K, Kobayashi Y, Koide M, Uehara S, Okamoto M, Ishihara A, et al. The Regulation of Bone Metabolism and Disorders by Wnt Signaling. Int J Mol Sci 2019;20. 371 https://doi.org/10.3390/ijms20225525. 372 Tan KCB, Chow W-S, Ai VHG, Metz C, Bucala R, Lam KSL. Advanced glycation end 373 [12] products and endothelial dysfunction in type 2 diabetes. Diabetes Care 2002;25:1055–9. 374 375 https://doi.org/10.2337/diacare.25.6.1055. Kume S, Kato S, Yamagishi S, Inagaki Y, Ueda S, Arima N, et al. Advanced glycation [13] 376 377 end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 2005;20:1647–58. 378 https://doi.org/10.1359/JBMR.050514. 379

Sanguineti R, Storace D, Monacelli F, Federici A, Odetti P. Pentosidine effects on human 380 osteoblasts in vitro. Ann N Y Acad Sci 2008;1126:166-72. 381 382 https://doi.org/10.1196/annals.1433.044. [15] Yamamoto M, Sugimoto T. Advanced Glycation End Products, Diabetes, and Bone 383 Strength. Curr Osteoporos Rep 2016;14:320–6. https://doi.org/10.1007/s11914-016-0332-384 385 1. Furst JR, Bandeira LC, Fan W-W, Agarwal S, Nishiyama KK, McMahon DJ, et al. 386 387 Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes. J Clin Endocrinol Metab 2016;101:2502–10. https://doi.org/10.1210/jc.2016-1437. 388 389 [17] García-Martín A, Rozas-Moreno P, Reyes-García R, Morales-Santana S, García-Fontana B, García-Salcedo JA, et al. Circulating levels of sclerostin are increased in patients with 390 391 type 2 diabetes mellitus. J Clin Endocrinol Metab 2012;97:234–41. https://doi.org/10.1210/jc.2011-2186. 392 Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, et al. Circulating 393 [18] sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 394 2012;97:1737–44. https://doi.org/10.1210/jc.2011-2958. 395 Yamamoto M, Yamauchi M, Sugimoto T. Elevated sclerostin levels are associated with 396 [19] 397 vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013;98:4030–7. https://doi.org/10.1210/jc.2013-2143. 398 Longo KA, Wright WS, Kang S, Gerin I, Chiang S-H, Lucas PC, et al. Wnt10b inhibits 399 [20] development of white and brown adipose tissues. J Biol Chem 2004;279:35503–9. 400 https://doi.org/10.1074/jbc.M402937200. 401

[21] Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, et al. Regulation 402 403 of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A 404 2005;102:3324–9. https://doi.org/10.1073/pnas.0408742102. 405 [22] Kubota T, Michigami T, Ozono K. Wnt signaling in bone metabolism. J Bone Miner Metab 2009;27:265–71. https://doi.org/10.1007/s00774-009-0064-8. 406 [23] Zhang J, Motyl KJ, Irwin R, MacDougald OA, Britton RA, McCabe LR. Loss of Bone 407 and Wnt10b Expression in Male Type 1 Diabetic Mice Is Blocked by the Probiotic 408 409 Lactobacillus reuteri. Endocrinology 2015;156:3169–82. https://doi.org/10.1210/EN.2015-1308. 410 411 Hoeppner LH, Secreto F, Jensen ED, Li X, Kahler RA, Westendorf JJ. Runx2 and bone [24] morphogenic protein 2 regulate the expression of an alternative Lef1 transcript during 412 413 osteoblast maturation. J Cell Physiol 2009;221:480–9. https://doi.org/10.1002/jcp.21879. 414 [25] Khan MP, Singh AK, Joharapurkar AA, Yadav M, Shree S, Kumar H, et al. Pathophysiological Mechanism of Bone Loss in Type 2 Diabetes Involves Inverse 415 Regulation of Osteoblast Function by PGC-1α and Skeletal Muscle Atrogenes: AdipoR1 416 as a Potential Target for Reversing Diabetes-Induced Osteopenia. Diabetes 2015;64:2609— 417 23. https://doi.org/10.2337/db14-1611. 418 419 [26] Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol 2006;4:e115. 420 421 https://doi.org/10.1371/journal.pbio.0040115. Dejmek J, Säfholm A, Kamp Nielsen C, Andersson T, Leandersson K. Wnt-5a/Ca2+-422 [27] induced NFAT activity is counteracted by Wnt-5a/Yes-Cdc42-casein kinase 1alpha 423

signaling in human mammary epithelial cells. Mol Cell Biol 2006;26:6024–36. 424 https://doi.org/10.1128/MCB.02354-05. 425 426 [28] Oishi I, Suzuki H, Onishi N, Takada R, Kani S, Ohkawara B, et al. The receptor tyrosine 427 kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells 2003;8:645–54. https://doi.org/10.1046/j.1365-2443.2003.00662.x. 428 [29] Maeda K, Kobayashi Y, Udagawa N, Uehara S, Ishihara A, Mizoguchi T, et al. Wnt5a-429 Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances 430 431 osteoclastogenesis. Nat Med 2012;18:405–12. https://doi.org/10.1038/nm.2653. McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N, Marquez R, et al. Role that 432 433 phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J 2005;24:1571–83. https://doi.org/10.1038/sj.emboj.7600633. 434 Chen Y, Chen L, Huang R, Yang W, Chen S, Lin K, et al. Investigation for GSK3B 435 [31] expression in diabetic osteoporosis and negative osteogenic effects of GSK3β on bone 436 marrow mesenchymal stem cells under a high glucose microenvironment. Biochem 437 Biophys Res Commun 2021;534:727–33. https://doi.org/10.1016/j.bbrc.2020.11.010. 438 Nunez Lopez YO, Iliuk A, Petrilli AM, Glass C, Casu A, Pratley RE. Proteomics and 439 [32] 440 Phosphoproteomics of Circulating Extracellular Vesicles Provide New Insights into 441 Diabetes Pathobiology. Int J Mol Sci 2022;23. https://doi.org/10.3390/ijms23105779. Xia H, Scholtes C, Dufour CR, Ouellet C, Ghahremani M, Giguère V. Insulin action and 442 [33] 443 resistance are dependent on a GSK3β-FBXW7-ERRα transcriptional axis. Nat Commun 2022;13:2105. https://doi.org/10.1038/s41467-022-29722-6. 444

445 Farr JN, Drake MT, Amin S, Melton LJ, McCready LK, Khosla S. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 446 2014;29:787–95. https://doi.org/10.1002/jbmr.2106. 447 448 [35] Hunt HB, Torres AM, Palomino PM, Marty E, Saiyed R, Cohn M, et al. Altered Tissue Composition, Microarchitecture, and Mechanical Performance in Cancellous Bone From 449 450 Men With Type 2 Diabetes Mellitus. J Bone Miner Res 2019;34:1191–206. https://doi.org/10.1002/jbmr.3711. 451 [36] 452 Andrade VFC, Chula DC, Sabbag FP, Cavalheiro DD da S, Bavia L, Ambrósio AR, et al. Bone Histomorphometry in Young Patients With Type 2 Diabetes is Affected by Disease 453 Control and Chronic Complications. J Clin Endocrinol Metab 2020;105. 454 455 https://doi.org/10.1210/clinem/dgz070. 456 Weivoda MM, Youssef SJ, Oursler MJ. Sclerostin expression and functions beyond the [37] osteocyte. Bone 2017;96:45–50. https://doi.org/10.1016/j.bone.2016.11.024. 457 458 459 460 461 462 463 464

Table 1. Clinical features of the study subjects

465

466

469

470

471

	T2D subjects	Non-diabetic	P value
	(n=15)	subjects	
		(n=21)	
Age (years)	73.00 (67.00-80.00)	73.00 (68.50-79.00)	0.644
BMI (kg/m²)	30.81 (24.44-34.00)	25.00 (24.00-31.50)	0.117
Menopausal age (years)	50.00 (42.50-52.75)	52.00 (48.00-53.00)	0.344
Fasting glucose levels (mg/dl)	112.00 (104.00-130.0)	94.00 (87.25-106.3)	**0.009
Disease duration (years)	14.50 (7.25-19.25)	-	-
HbA1c (%)	6.95 (6.37-7.37)	-	-
Serum calcium (mg/dl)	9.05 (8.800-9.550)	9.15 (9.000-9.550)	0.535
eGFR (mL/min/1.73 m <sup>2</sup> )	78,30 (59.90-91.10)	75.60 (61.35-88.55)	0.356
Serum blood urea nitrogen (mg/dl)	42.00 (36.00-53.00)	37.00 (31.75-46.50)	0.235

Table 1. Results were analyzed using unpaired T-test with Welch's correction. Results arepresented as median and percentiles (25th and 75th).

# **Table 2.** Histomorphometric parameters of trabecular bone of the study subjects

472

473

	T2D subjects	Non-diabetic	P value
	(n=8)	subjects	
		(n=9)	
BV/TV (%)	0.248 (	0.358 (0.271-	0.120
	0.157-0.407 )	0.456)	
Md.V/BV (%)	0.994(0.984-	0.995 (0.985-	0.998
	0.998)	0.997)	
Md.V/TV (%)	0.249 (0.156-	0.352 (0.269-	0.053
	0.366)	0.454)	
OV/BV (%)	0.009 (0.002- 0.009)	0.004 (0.002- 0.015)	0.704
OV/TV (%)	0.001 (0.0002- 0.0058)	0.001 (0.0007- 0.0056)	0.896
OS/BS (%)	0.026 (0.022-	0.035 (0.009- 0.117)	0.525
	0.161)	,	

**Table 2.** Results were analyzed using unpaired T-test with Welch's correction and are presented

as median and percentiles (25th and 75th).


# **Table 3.** Bone mechanical parameters of trabecular bone of the study subjects

	T2D subjects	Non-diabetic	P value
	(n=10)	subjects	
		(n=21)	
Young's modulus (MPa)	21.60 (13.46-	76.24 (26.81-	0.002
	30.10)	132.9)	
Ultimate strength (MPa)	3.015 (2.150-	7.240 (3.150-	0.914
	13,86)	8.898)	
Yield strength (MPa)	2.525 (1.943-	6.150 (3.115-	0.159
	6.393)	7.423)	

**Table 3.** Results were analyzed using unpaired T-test with Welch's correction and are presented as median and percentiles (25th and 75th).


## Figure 1.

486




## Figure 2.

504




# Figure 3.



## Figure 4.

519

521



## Figure Legends

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

Figure 1. Gene expression analysis in trabecular bone samples. (A) SOST mRNA levels resulted higher in T2D subjects versus Nondiabetic subjects (p<0.0001). (B) DKK-1 mRNA expression level was not different between groups (p=0.2022). (C) LEF-1 mRNA levels resulted lower in T2D subjects versus nondiabetics subjects (p=0.0136). (D) WNT10B mRNA expression level was lower in T2D subjects versus nondiabetic subjects (p=0.0302). (E) WNT5A mRNA resulted higher in T2D subjects versus nondiabetics subjects (p=0.0232). (F) COL1A1 mRNA levels resulted lower in T2D subjects versus Nondiabetic subjects (p=0.0482). (G) GSK3B mRNA levels resulted higher in T2D subjects versus Nondiabetic subjects (p=0.0456). (H-J) AXIN2, BETA-CATENIN, SFRP5 mRNA levels were not different between groups (p=0.2296, p=0.3073; p=0.1390). Data are expressed as fold changes over beta-actinMedians and interquartile ranges, differences between non-diabetics and T2D subjects were analyzed using Mann-Whitney test. Figure 2. Relationship between AGEs (µg quinine/g collagen) bone content and mRNA level of the Wnt signaling key genes in T2D and non-diabetic subjects. (A) LEF-1 negatively correlated with AGEs (r=-0.7500; p=0.0255). (B) COL1A1 negatively correlated with AGEs (r=-0.9762; p=0.0004). (C) SOST mRNA level expression positively correlated with AGEs (r=0.9231; p<0.0001). (D) WNT5A mRNA expression level positively correlated with AGEs (r=0.6751; p=0.0322). (E) WNT10B mRNA expression level was not correlated with AGEs (r=-0.4883; p=0.1938). (F) DKK1 mRNA expression level was not correlated with AGEs (r=0.0476; p=0.9349). (G) GSK3B mRNA expression level was positively correlated with AGEs (r=0.7500; p=0.0255). (H) SFRP5 mRNA expression level was positively correlated with AGEs (r=0.7167; p=0.0369). (I) AXIN2 and (J) SFRP5 mRNA expression levels were not correlated with AGEs

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566


567

568


(r=0.5500, p=0.1328; r=0.2167, p=0.5809). Data were analyzed using nonparametric Spearman correlation analysis and r represents the correlation coefficient. Figure 3. Relationship between fasting glucose levels (mg/dl) and disease duration with SOST and WNT5A mRNA levels. (A) SOST positively correlated with fasting glucose levels (r=0.4846; p=0.0043). (B) SOST positively correlated with disease duration (r=0.7107; p=0.0174). (C) WNT5A positively correlated with fasting glucose levels (r=0.5589; p=0.0037). (D) GSK3B positively correlated with fasting glucose levels (r=0.4901; p=0.0051). Data were analyzed using nonparametric Spearman correlation analysis and r represents the correlation coefficient. Figure 4. Relationship between Young Modulus (MPa), Ultimate strength (MPa) and Yield strength (MPa) with mRNA levels of the Wnt signaling key genes in T2D and non-diabetic subjects. (A) SOST negatively correlated with Young Modulus (MPa); (r=-0.5675; p=0.0011). (B) LEF-1 positively correlated with Young Modulus (MPa); (r=0.4116; p=0.0295). (C) WNT10B positively correlated with Young Modulus (MPa); (r=0.6697; p=0.0001). (D) AXIN2 negatively correlated with Young Modulus (MPa); (r=-0.5523; p=0.0042). (E) BETA-CATENIN negatively correlated with Young Modulus (MPa); (r=-0.5244; p=0.0050). (F) SFRP5 negatively correlated with Young Modulus (MPa); (r=-0.4442; p=0.0437). (G) WNT10B positively correlated with Ultimate strength (MPa); (r=0.5392; p=0.0054). (H) AXIN2 negatively correlated with Ultimate strength (MPa); (r=-0.4180; p=0.0472). (I) BETA-CATENIN negatively correlated with Ultimate strength (MPa); (r=-0.5528; p=0.0034). (J) LEF-1 positively correlated with Yield strength (MPa); (r=0.4338; p=0.0495). (K) WNT10B positively correlated with Yield strength (MPa); (r=0.6632; p=0.0020). (L) GSK3B negatively correlated with Yield strength (MPa); (r=-0.4674; p=0.0245). (M) AXIN2 negatively correlated with Yield strength

(MPa); (r=-0.5067; p=0.0319). (N) BETA-CATENIN negatively correlated with Yield strength (MPa); (r=-0.5491; p=0.0149). (O) SFRP5 negatively correlated with Yield strength (MPa); (r=-0.5357; p=0.0422). Data were analyzed using nonparametric Spearman correlation analysis and r represents the correlation coefficient.

## Supplementary figure 1.



# Supplementary figure 2.



# Legend of supplementary figures

606

**Supplementary figure 1**. Relationship between fasting glucose levels (mg/dl) and LEF-1, 607 608 WNT5A, WNT10B, DKK-1, COL1A1 mRNA levels. (A-E) Data showed negative correlations between fasting glucose levels (mg/dl) and (A) LEF-1 (r=-0.3649; p=0.0613), (B) WNT10B (r=-609 0.0041; p=0.9863), (C) COL1A1 (r=-0.1157; p=0.5354), (D) DKK-1 (r=-0.0947; p=0.6522) 610 611 mRNA levels. Data showed positive correlations between fasting glucose levels (mg/dl) with (E) 612 AXIN2 (r=0.0993; p=0.6442), (F) BETA-CATENIN (r=0.2371; p=0.1991) and (G) SFRP5 (r=0.3767; p=0.0696). Data were analyzed using nonparametric Spearman correlation analysis 613 and r represents the correlation coefficient. 614 615 Supplementary figure 2. Relationship between Young Modulus (MPa), Ultimate strength (MPa) and Yield strength (MPa) with mRNA levels of the Wnt signaling genes in T2D and non-616 617 diabetic subjects. (A) DKK-1 positively correlated with Young Modulus (MPa); (r=0.02857; p=0.9022). (B) COL1A1 positively correlated with Young Modulus (MPa); (r=0.2991; 618 p=0.1397). (C) GSK3B negatively correlated with Young Modulus (MPa); (r=-0.3127; 619 p=0.0814). (D) SOST negatively correlated with Ultimate strength (MPa); (r=-0.1468; 620 621 p=0.4001). (E) DKK-1 negatively correlated with Ultimate strength (MPa); (r=0.1353; p=0.5694). (F) LEF-1 positively correlated with Ultimate strength (MPa); (r=0.2790; p=0.1588). 622 (G) WNT5A negatively correlated with Ultimate strength (MPa); (r=-0.0143; p=0.9469). (H) 623 624 COL1A1 positively correlated with Ultimate strength (MPa); (r=0.2138; p=0.3047). (I) GSK3B negatively correlated with Ultimate strength (MPa); (r=-0.3482; p=0.0594). (J) SFPR5 625 negatively correlated with Ultimate strength (MPa); (r=-0.3789; p=0.0994). (K) SOST positively 626 627 correlated with Yield strength (MPa); (r=0.1009; p=0.6390). (L) DKK-1 positively correlated 628 with Yield strength (MPa); (r=0.2786; p=0.3139). (M) WNT10B negatively correlated with

Yield strength (MPa); (r=-0.0079; p=0.9744). (N) COL1A1 positively correlated with Yield strength (MPa); (r=0.2196; p=0.3260). (O) BETA-CATENIN negatively correlated with Young Modulus strength (MPa); (r=-0.1667; p=0.4953). (P) BETA-CATENIN negatively correlated with Ultimate strength (MPa); (r=-0.2797; p=0.2610). (Q) BETA-CATENIN negatively correlated with Yield strength (MPa); (r=-0.1813; p=0.5537). Data were analyzed using nonparametric Spearman correlation analysis and r represents the correlation coefficient.




Figure 1





Figure 2

260

400 AGEs (p.g quinine/g collagen)






Figure 4